News coverage about Bellicum Pharmaceuticals (NASDAQ:BLCM) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Bellicum Pharmaceuticals earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 47.3282180903316 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news articles that may have effected Accern Sentiment’s scoring:
A number of research analysts have recently commented on BLCM shares. Zacks Investment Research upgraded shares of Bellicum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 price target for the company in a research report on Wednesday, January 10th. Raymond James Financial restated a “buy” rating on shares of Bellicum Pharmaceuticals in a research report on Tuesday, December 12th. SunTrust Banks cut their target price on shares of Bellicum Pharmaceuticals to $18.00 and set a “buy” rating for the company in a research report on Wednesday, January 31st. Wells Fargo & Co lowered shares of Bellicum Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $6.00 target price for the company. in a research report on Wednesday, January 31st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $10.00 target price (down from $12.00) on shares of Bellicum Pharmaceuticals in a research report on Wednesday, January 31st. Two analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. Bellicum Pharmaceuticals currently has an average rating of “Hold” and an average target price of $15.43.
Bellicum Pharmaceuticals (NASDAQ:BLCM) traded up $0.10 during trading on Wednesday, reaching $5.87. 427,762 shares of the company’s stock traded hands, compared to its average volume of 1,050,000. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.08 and a quick ratio of 6.08. The company has a market capitalization of $195.21, a P/E ratio of -1.96 and a beta of 0.70. Bellicum Pharmaceuticals has a 1-year low of $5.02 and a 1-year high of $15.55.
In related news, CFO Alan A. Musso sold 17,117 shares of the stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $9.33, for a total value of $159,701.61. Following the completion of the transaction, the chief financial officer now directly owns 31,585 shares of the company’s stock, valued at $294,688.05. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Bros. Advisors Lp Baker sold 880,735 shares of the stock in a transaction dated Friday, January 19th. The stock was sold at an average price of $8.20, for a total transaction of $7,222,027.00. The disclosure for this sale can be found here. Insiders sold 1,165,145 shares of company stock valued at $9,696,662 over the last three months. 18.77% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: “Bellicum Pharmaceuticals (NASDAQ:BLCM) Getting Somewhat Positive News Coverage, Analysis Finds” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/14/bellicum-pharmaceuticals-blcm-getting-somewhat-favorable-news-coverage-analysis-finds-3.html.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.